Savoxepin mesylate | CAS#79262-47-8

MedKoo Cat#: 526251 | Name: Savoxepin mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Savoxepin mesylate is a tetracyclic cyano-dibenzoxepino-azepine derivative with potent antidopaminergic activity.

Chemical Structure

Savoxepin mesylate

CAS#79262-47-8 (mesylate)

Theoretical Analysis

MedKoo Cat#: 526251

Name: Savoxepin mesylate

CAS#: 79262-47-8 (mesylate)

Chemical Formula: C26H30N2O4S

Exact Mass: 466.1926

Molecular Weight: 466.60

Elemental Analysis: C, 66.93; H, 6.48; N, 6.00; O, 13.72; S, 6.87

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

79262-46-7 (free base) 79262-47-8 (mesylate)

Synonym

Savoxepin mesylate; CGP 19486A; CGP-19486A; Savoxepin mesilate.

IUPAC/Chemical Name

1H-Dibenz(2,3:6,7)oxepino(4,5-d)azepine-7-carbonitrile, 3-(cyclopentylmethyl)-2,3,4,5-tetrahydro-, methanesulfonate (1:1)

InChi Key

PDYLRPIUJQGVNY-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H26N2O.CH4O3S/c26-16-19-9-10-25-23(15-19)21-12-14-27(17-18-5-1-2-6-18)13-11-20(21)22-7-3-4-8-24(22)28-25;1-5(2,3)4/h3-4,7-10,15,18H,1-2,5-6,11-14,17H2;1H3,(H,2,3,4)

SMILES Code

N#CC1=CC=C(OC2=CC=CC=C23)C(C4=C3CCN(CC5CCCC5)CC4)=C1.CS(=O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 466.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Volz HP, Möller HJ, Gerebtzoff A, Bischoff S. Savoxepine versus haloperidol. Reasons for a failed controlled clinical trial in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2002 Apr;252(2):76-80. PubMed PMID: 12111340. 2: Lefèvre G, Duval M, Botta L, Godbillon J. Direct microtitre plate radioimmunoassay of savoxepine in unextracted plasma. J Immunoassay. 1996 Feb;17(1):29-46. PubMed PMID: 8926305. 3: Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl). 1995 Jul;120(2):128-33. PubMed PMID: 7480543. 4: Cascella NG, Tarazi FI, Shirakawa O, Tamminga CA. Savoxepine fails to selectively influence glucose metabolism in the rat limbic system. Psychopharmacology (Berl). 1994 Mar;114(2):275-80. PubMed PMID: 7838920. 5: Allémann E, Leroux JC, Gurny R, Doelker E. In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res. 1993 Dec;10(12):1732-7. PubMed PMID: 7905625. 6: Leenders KL, Antonini A, Thomann R, Locher JT, Maître L, Gerebtzoff A, Beer HF, Ametamey S, Weinreich R, Gut A, et al. Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). Eur J Clin Pharmacol. 1993;44(2):135-40. PubMed PMID: 8095895. 7: Herrmann WM, Schärer E, Wendt G, Delini-Stula A. Pharmaco-EEG profile of maroxepine: third example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs. Pharmacopsychiatry. 1991 Nov;24(6):214-24. PubMed PMID: 1812498. 8: Herrmann WM, Schärer E, Wendt G, Delini-Stula A. Pharmaco-EEG profile of levoprotiline: second example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs. Pharmacopsychiatry. 1991 Nov;24(6):206-13. PubMed PMID: 1812497. 9: Herrmann WM, Schärer E, Delini-Stula A. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine. Pharmacopsychiatry. 1991 Nov;24(6):196-205. PubMed PMID: 1687485. 10: Wetzel H, Wiedemann K, Holsboer F, Benkert O. Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients. Psychopharmacology (Berl). 1991;103(2):280-3. PubMed PMID: 1674161. 11: Möller HJ, Kissling W, Dietzfelbinger T, Stoll KD, Wendt G. Efficacy and tolerability of a new antipsychotic compound (savoxepine): results of a pilot-study. Pharmacopsychiatry. 1989 Jan;22(1):38-41. PubMed PMID: 2565583. 12: Bischoff S, Christen P, Vassout A. Blockade of hippocampal dopamine (DA) receptors: a tool for antipsychotics with low extrapyramidal side effects. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(4):455-67. PubMed PMID: 2900538. 13: Butler B, Bech P. Neuroleptic profile of cipazoxapine (Savoxepine), a new tetracyclic dopamine antagonist: clinical validation of the hippocampus versus striatum ratio model of dopamine receptors in animals. A preliminary report. Pharmacopsychiatry. 1987 May;20(3):122-6. PubMed PMID: 2885867.